🕵️ Lyell Immunopharma, Inc. ($LYEL)
SEC insider & ownership activity, last 12 months · CIK 1806952 · every row links its SEC filing
Over the last 12 months insiders sold $527K against $25.0M of open-market buying. ARCH Venture Fund XIII, L.P. bought $12.5M in discretionary trades (Mar). Innovative Cellular Therapeutics Holdings Limited added 9.8% → 12.3%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
2 buyers, $25.0M (2 lots) · 7 sellers, $527K (32 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| ARCH Venture Fund XIII, L.P. | 1 | $12.5M | 0 | – | Mar 6, 2026 |
| ARCH Venture Partners IX, LLC | 1 | $12.5M | 0 | – | Mar 6, 2026 |
| Seely Lynn | 0 | – | 7 | $283K | May 11, 2026 |
| Bulis Veronica Sanchez | 0 | – | 5 | $88K | May 11, 2026 |
| Gary K. Lee | 0 | – | 7 | $65K | May 11, 2026 |
| Stephen J. Hill | 0 | – | 7 | $47K | May 11, 2026 |
| Shook David | 0 | – | 1 | $25K | Jun 10, 2026 |
| Charles W. Newton | 0 | – | 3 | $18K | Aug 21, 2025 |
| Innovative Cellular Therapeutics Holdings Ltd | 0 | – | 2 | $274 | Jul 17, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| ARCH Venture Fund IX Overage, L.P. | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| ARCH Venture Fund XIII, L.P. | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| ARCH Venture Partners IX, L.P. | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| ARCH Venture Partners IX Overage, L.P. | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| ARCH Venture Partners IX, LLC | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| ARCH Venture Partners XIII, L.P. | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| ARCH Venture Partners XIII, LLC | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| Keith Crandell | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| Robert Nelsen | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| Kristina Burow | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| Steven Gillis | 13.9% | 13G | May 15, 2026 | filing ↗ | |
| Innovative Cellular Therapeutics Holdings Limited | 12.3% | 13G | Jun 18, 2026 | filing ↗ | |
| Clinton Bybee | 7.8% | 13G | May 15, 2026 | filing ↗ | |
| James B. Tananbaum | 7.6% | 13G | Nov 14, 2025 | filing ↗ | |
| Euler Fund, L.P. | 6.7% | 13G | Apr 21, 2026 | filing ↗ | |
| Euler Managers Limited | 6.7% | 13G | Apr 21, 2026 | filing ↗ | |
| Antonis Indianos | 6.7% | 13G | Apr 21, 2026 | filing ↗ | |
| James Tananbaum | 6.7% | 13G | Feb 14, 2025 | filing ↗ | |
| Explore Investments LLC | 6.6% | 13G | May 8, 2026 | filing ↗ | |
| Jeffrey P. Bezos | 6.6% | 13G | May 8, 2026 | filing ↗ | |
| Paul Berns | 6.1% | 13G | May 15, 2026 | filing ↗ | |
| Gates Frontier, LLC | 5.6% | 13G | Aug 1, 2025 | filing ↗ | |
| William H. Gates III | 5.6% | 13G | Aug 1, 2025 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Shareholder vote (5.07) | Jun 10, 2026 | filing ↗ |
| Earnings (2.02) | May 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 6, 2026 | filing ↗ |
| Earnings (2.02) | Mar 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 12, 2026 | filing ↗ |
| Officer/director changes (5.02) | Mar 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 6, 2026 | filing ↗ |
| Other events (8.01) | Dec 7, 2025 | filing ↗ |
| Charter/bylaw changes (5.03) | Dec 3, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 3, 2025 | filing ↗ |
| Earnings (2.02) | Nov 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 12, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 6, 2025 | filing ↗ |
| Unregistered equity sale (3.02) | Nov 6, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 6, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 6, 2025 | filing ↗ |
| Officer/director changes (5.02) | Oct 31, 2025 | filing ↗ |
| Officer/director changes (5.02) | Sep 15, 2025 | filing ↗ |
| Earnings (2.02) | Aug 12, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 12, 2025 | filing ↗ |